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decreasing trend in average CNI dose by year: at the end of the first year, the mean
dose of TAC was 9.35.4 mg/day and 282.1118.3 mg/day for CYC, decreasing to
5.23.6 and 158.757.8 mg/day in the third year, and 4.87.3 and 144.258.4 mg/
day in the fifth year. At the end of the first (n455) and second year (n408) post-
transplant, the most common IS regimens were TAC/prednisone/mycophenolate
mophetil (MMF) (19.1% in both years), TAC/prednisone/azathioprine (15.6% at first
year and 14.7% at second year) and CyC/prednisone/azathioprine (13.2% at first
year and 14.0% at second year). By the end of the fifth year (n141), however, the
most common IS regimen was TAC/prednisone/mycophenolate sodium (MFS;
31.9%), followed by CyC/prednisone/MFS (7.8%) and TAC/prednisone/MMF (7.1%).
CONCLUSIONS:Tacrolimuswas the CNI of choice for themajority of de novo kidney
transplant patients in 2004. The main IS therapy regimens during the first post-
transplant years was tacrolimus/prednisone/mycophenolate mophetil.
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OBJECTIVES: The employer burden of CKD in terms of lost productivity, short and
long term disability use, and high total health care costs has been well-docu-
mented and warrants an employer-sponsored population health management
program to improve the health and lives of theworkforce. Georgia Power Company
(GPC) has implemented a chronic care management program aimed at early iden-
tification, disease awareness, and counseling of employees through on-site
screenings. METHODS: Individuals are offered voluntary participation in the CKD
management programwith their PCPs andnephrologists depending upon their risk
and CKD stage. Health outcomes including, clinical, resource utilization, and self-
reported health status and productivity are compared pre- and post- program
implementation. RESULTS: Preliminary results at the 6-month mark show that: a)
2,589 employees were screened, 638 (25%) met program criteria for participation
and 110 (17.2%) agreed to participate in the study; b) among the current enrollees,
17% have diabetes and 51% have hypertension; c) mean eGFR rates are 61.27, and
HbA1C levels of 7.7, and a mean BMI of 30.5 indicating a population at high risk for
developing CKD; d) participants reported missing on average 10.5 hours/week due
to their CKD; and e) baseline total health care expenditures were $19,776 permem-
ber per year indicating a high cost population as well. CONCLUSIONS: CKD is a
high-cost disease for GPC. Resources invested in creating novel CKD management
programs to identify, raise awareness, and manage CKD are a worthwhile invest-
ment for employers.
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OBJECTIVES:Many patients with OAB attempt self-management and are reluctant
to initiate an OAB discussion with a physician. We sought to identify patient char-
acteristics associatedwith patient initiation of anOAB discussionwith a physician.
METHODS: Of 24,866 respondents of the 2009 National Health & Wellness Survey,
an internet-based questionnaire onhealthcare attitudes, behaviors, and outcomes,
2750 recontacted respondents qualified for and completed a longitudinal survey.
Eligible subjects (18 y) had an OAB Awareness Total score of 14 (men) or 16
(women) or used an OAB prescription medication. Exclusion criteria included cur-
rent pregnancy or catheter use, hematuria, urinary tract infection symptoms, be-
nign prostatic hyperplasia (BPH), use of BPH medication, or prostate cancer. Anal-
ysis of proportions and logistic regression analysis (2-tailed P0.05 significance
level) identified patient characteristics associated with initiation of OAB discus-
sions with a physician. RESULTS: 1325 of 2750 (48%) OAB patients reported initiat-
ing an OAB discussion with a physician. These respondents (mean age 52 y) were
predominantly female (65%) and white (71%). Significant variables associated with
initiation of an OAB discussion were divorced/separated/widowed vs single, more
familiar with OAB, a longer duration of bladder control symptoms, lower SF-12
Physical Component Summary score, better daily activity function, greater pill
burden, and regular physician contact (Table). Patient age, income, employment
status, and health insurance coverage were not significantly associated with a
patient-physician OAB discussion. CONCLUSIONS: Patients are more likely to ini-
tiate an OAB discussion with their physician if they have regular contact with the
physician, a longer duration of symptoms, are familiar with OAB, and have worse
physical quality of life. Socioeconomic variables or drug insurance coverage were
not significantly associated. These findings suggest that the physician relationship
is important for help seeking behavior; and there is a need for early patient educa-
tion on OAB symptoms and treatments.
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OBJECTIVES: Determine the impact of correcting for different definitions of pros-
tate-specific antigen (PSA) recurrence when analyzing relative effectiveness of
seven treatments for localized PC; Emphasize the importance of clinical input and
real-world data in ensuring modeling accuracy. METHODS: We conducted two
lifetime cost-utility analyses comparing men undergoing open, laparoscopic, or
robot-assisted radical prostatectomy, 3-dimensional conformal or intensity-mod-
ulated radiation therapy, brachytherapy, or combined external-beam radiation
and brachytherapy.We constructed aMarkovmodel quantifying lifetime costs and
quality-adjusted life years (QALYs) for men with localized PC in low-, intermedi-
ate-, and high-risk strata. Post-treatment PSA recurrence is defined differently for
surgical versus radiation treatments. In Study 1, we made clinically-based correc-
tions in time between recurrence and metastasis, the basis for time-to-disease-
progression (biochemical failure [BCF]) calculations, to account for the different
definitions. In Study 2, these corrections were not made. RESULTS: In “corrected”
analyses, surgery tended to yieldmore QALYs and lower costs than radiation, with
minimal differences among surgicalmodalities. Compared to a base case assuming
a 4-year increment between the surgery and radiation modalities in the median
time from BCF to metastasis, “uncorrected” analyses yield surgical costs relatively
overstated by 3 to 11%; QALYs understated by 1 to11%; life expectancy understated
by1% to 8.5%;metastasis overstated by 17 to 36%; and PC death overstated by 17%
to 43%. Results are generally greater with larger corrections and outcomes dis-
counted to net present value. CONCLUSIONS: “Without correction” results do not
affect conclusions about relative costs for all patients or QALYs for low-risk pa-
tients. They do affect QALY conclusions for intermediate- and higher-risk patients,
yielding erroneous conclusions on the relative superiority of radiation versus sur-
gical treatments. Without correction, the same incorrect conclusions would be
reached for survival, metastasis, and PC death. Literature and real-world datawere
used to validate the corrections.
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OBJECTIVES: Selection of an appropriatemodeling structure is a key consideration
in economic evaluations. Factors that influence the choice of modeling structure
include data availability and consensus within the clinical community regarding
clinically meaningful definitions of treatment response and defined and measure-
able health states. In the absence of an agreed consensus, selecting a model struc-
ture is challenging. We explored twomodel structures to assess the cost-effective-
ness of onabotulinumtoxinA for the treatment of urinary incontinence (UI) due to
neurogenic detrusor overactivity (NDO).METHODS: Themerits and limitations of a
model based on treatment response versus an absolute model structure were con-
sidered. In the response model, health states were defined by precise trial out-
comes (percent reduction in UI episodes from baseline). In the absolute model,
health states were defined by categories of UI episodes/week. In the absence of
clinically meaningful cutoffs, we plotted health-related quality of life (HRQoL)
scores versus UI episodes to derive meaningful cutoffs for health states based on
HRQoL. RESULTS: In the response model, response was defined as a 50% reduc-
tion in UI episodes. The primary limitation with this approach is the heterogeneity
within ‘non-responder’ patients (e.g. patients with either a 0% or a 49% reduction
are both ‘non-responders’). No clear health state cutoffs were observed with re-
spect to HRQoL and UI episodes for the absolute model. Health states were defined
on percentile distribution within the trial population: dry, 0-25% [1-14 UI episodes/
week],25%-75% [15-32 UI episodes/week], and75% [32 UI episodes/week]. The
primary limitations to this approach are the inability to capture health improve-
ment within health states and the lack of clinical relevance for health states based
on percentiles. CONCLUSIONS: In the absence of clinical consensus, model struc-
ture selection should be a key consideration to capture the true economic value of
a therapy.
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OBJECTIVES: Retrospective analyses are inherently subject to bias. Techniques
such as propensity score matching (PSM) can function as pseudo-randomization.
The PSM, however, is often done solely using administrative claims data.We tested
the hypothesis that claims alone would provide inadequate matching when com-
pared to claims plus relevant biomarkers. METHODS: We used databases from a
large dialysis organization to obtain two cohorts of dialysis patients prescribed
different drug therapies within the same class. The cohorts were first matched on
demographics and comorbidities only. The same cohorts were then rematched,
adding baseline biomarkers (albumin, corrected calcium, Kt/V, normalized protein
catabolic rate (nPCR), parathyroid hormone (PTH), phosphorus) to the PSM. We
used generalized mixed models (GMM) to determine if treatment was associated
with lab outcomes over a 16-week period, run separately on both PSM cohorts.
RESULTS: The first PSM cohorts did not differ on baseline demographic and comor-
bid variables, but significant differences existed in four (nPCR, phosphorus, cal-
cium, PTH) of the six baseline biomarkers excluded from the match (all p 0.01).
When biomarkers were included in the PSM, there were no significant differences
between groups on any baseline measures. GMM analysis showed a significant
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association between drug and lab outcomes for the cohort matched on demo-
graphic and comorbid information only (p0.001). There was no significant asso-
ciation in the cohort matched on biomarkers plus comorbid and demographic
variables (p0.414). CONCLUSIONS: PSM using administrative claims alone left
considerable channeling bias in the sample, and erroneous conclusions were
drawn from subsequent GMM analysis. Inclusion of biomarkers in the PSM re-
moved this bias and yielded non-significant GMM results. Administrative claims
data without biomarkers may not be sufficient for conducting PSM.
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OBJECTIVES: This study evaluated the benefits of VNS Therapy on health resource
utilization (HRU), epilepsy-related comorbidities, and costs over time in drug-re-
sistant epilepsy patients in a clinical practice setting. METHODS: An open-cohort
pre-post analysis was conducted using Medicaid data from FL, NJ, IA, MO, and KS
(January 1997-June 2009). Patients had1 neurologist visit with epilepsy diagnosis
(ICD-9 345.xx, 780.3, or 780.39), 1 procedure for VNS Therapy implantation, 1
anti-epileptic drug (AED), 6 months of pre- and post-VNS Therapy continuous
enrollment. The 6-months precedingVNSTherapy implantationwas designated as
Pre-VNS Therapy period. Post-VNS Therapy periodwas designated from the date of
VNS Therapy implantation until removal of device, death, or Medicaid disenroll-
ment. Univariate and multivariate Poisson regressions (incidence rate ratios [IRR]
and 95% confidence intervals [CI]) compared HRU and epilepsy-related comorbidi-
ties and GLM models estimated cost differences between the pre- and post-VNS
Therapy periods. Costs were adjusted to $2009 using medical care component of
the consumer price index. RESULTS:Of the 1655 patients, mean age was 29.4 years
and 51.4% were males. Compared to Pre-VNS Therapy period the incidence of
hospitalizations and emergency room (ER) visits decreased over time during Post-
VNS Therapy period (Trend: 0.9238, p.0001 and Trend: 0.9526, p.0001, respec-
tively). Generalized tonic-clonic seizure events showed a decreasing trend during
Post-VNS Therapy period than Pre-VNS Therapy period (adjusted IRR: 1.23 [CI:
1.03-1.46] in Q1 to 0.17 [CI: 0.11-0.27] in Q12). During Post-VNS Therapy period,
average total health care costs decreased from $42,540 (Q1) to $14,316 (Q12). After
1.5 years, cost savings in Post-VNSTherapy period started to outweigh total costs of
VNS Therapy device and implantation procedures. CONCLUSIONS: To conclude,
VNS Therapy is associated with decreased HRU and common epilepsy-related co-
morbidities, such as hospitalizations, ER visits and generalized tonic-clonic seizure
events, resulting in net cost savings for public payers after about 1.5 years.
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OBJECTIVES:MildAlzheimer’sDisease (AD) is oftendifficult todifferentiate frommild
cognitive impairment (MCI) or non-ADdementias. Amultitude of diagnostic biomark-
ers and advanced imaging strategies have been developed to aid in the diagnosis and
management of AD. Examples of biomarkers include total tau, phosphorylated tau
(Ptau), and the 42 amino acid form of beta-amyloid (A1-42) and imaging strategies
include MRI, FDG-PET, SPECT and CT. We sought to systematically review and meta-
analyze the published evidence on key test characteristics of major diagnostic strate-
gies in AD. METHODS: A systematic review was undertaken to locate all studies of
biomarkers or diagnostic imaging for AD published in English from January 1990 to
March 2010. Meta-analysis was performed using a bivariate mixed-effects binary re-
gression model. We calculated sensitivity (SN), specificity (SP) and area under the
receiver operating curves (AUROC), with confidence and prediction contours in order
to formulate best estimates of SN and SP of commonly used diagnostic tests for AD.
RESULTS:Of 1,840unique studies identified, 119 presentedprimary data sufficient for
analysis. For each diagnostic method, SN and SP were calculated against non-de-
mented controls, non-AD dementias with andwithout MCI, if available. Compared to
non-demented controls, FDG-PET demonstrated the highest AUROC (0.96), with 90%
SN (95%CI 84% to 94%) and 89% SP (95% CI 81% to 94%). FDG-PET also wasmost accu-
rate in discriminating AD from demented controls (including MCI) with AUROC 0.91,
and 92% SN (95%CI 84% to 96%) and 78% SP (95% CI 69% to 85%). For discrimination of
AD from non-AD dementias (excluding MCI), CSF Ptau and SPECT produced identical
AUROC (0.86)with 79%and86%SNand80%and81%SP, respectively.CONCLUSIONS:
Diagnostic strategies for AD show wide variation in test characteristics and some
show promise for clinical practice.
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OBJECTIVES: Despite well conducted treatment, schizophrenic patients often re-
main symptomatic. Although multiple studies studied resistant patients, no data
are available on partial responders (PR). The purpose of this study is to compare
clinical, quality of life (QoL), cost of PR versus non symptomatic patients (full
respondersFR), and to assess the evolution of PR. METHODS: An analysis was
performed based on a sample of patients in France and UK followed prospectively
over 2 years. At baseline, resistant as well as acute exacerbated patients were
excluded. Symptomatic patients were defined according to 3 clinical criteria: CGI
score 4 and PANSS score 60 (with 3 items 4). Evolution was assessed over the
2 years period. The following information was collected using standardized vali-
dated instruments: psychotic symptoms, depression, side effects, compliance,
functioning, specific and generic QoL, resource utilisation. RESULTS: 93 (19%) pa-
tients were identified as PR and 284 (59%) as FR out of 484 patients. The population
of PR was well discriminated at baseline period when compared to FR. Clinical
symptoms including depression and side effects, compliance, functioning, QoL are
more severe in PR than in FR. Cost of management of PR appears significantly
higher than FR. Patients identified as PR remained PR over the 2 years period. The
change of prescription including switch, dosage increase or therapy augmentation
is similar between PR and FR. CONCLUSIONS: The PR is a stable population over-
time with higher clinical burden and increased management cost compared to FR.
The lack of specific treatment pattern raises the issue of the need for specific
disease management strategy of PR and related assessment of such intervention.
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MULTIDISCIPLINARY FRENCH SURVEY (SUPFER SURVEY)
Lasocki S1, Luporsi E2, Jamin C3, Darne B4, Mahi L5, Marteau P6
1CHU Bichat-Claude Bernard, Paris, France, 2Centre Alexis Vautrin, Vandoeuvre-Les-Nancy,
France, 3AFACS, Paris, France, 4Monitoring Force SAS, Maisons Laffitte, France, 5Vifor Pharma
AG, Neuilly sur Seine, France, 6CHU Lariboisière, Paris, France
OBJECTIVES: To assess the perception of iron deficiency and describe themanage-
ment of iron deficiency in clinical practices.METHODS: Physicians were randomly
selected from a professional directory. They reported in a questionnaire the esti-
mated frequency of iron deficiency and anemia among their patients, the biological
exams performed for iron deficiency diagnosis and the conditions of use of intra-
venous iron. The survey analysis was performed on 358 questionnaires (return
rate: 12%) from physicians of different areas of expertise (anesthesia, intensive
care, surgery, n67; gynecology, obstetrics, n122; oncology, hematology, radio-
therapy, n39; hepato-gastroenterology, internal medicine, geriatrics, rheumatol-
ogy, n130). RESULTS:Out of 86% (309/358) of the physicians reported cases of iron
deficiency. For 63% of them (223/358), the frequency of anemia among their pa-
tients wasmore than 10%. Survey responders were 25% (89/358) to report that they
systematically explored iron deficiency and 61% (217/358) only if anemia had been
previously diagnosed. Severe iron deficiency, is treated with oral iron in 75% (269/
358), 39% (141/358) with intravenous iron and 20% (70/358) with transfusion. For
70% of the physicians who prescribe intravenous iron (148/213) the limit threshold
of hemoglobin for prescription of intravenous iron of 8 g/dL (median). In contrast
with hemoglobin level, serum ferritin and transferrin saturation,were infrequently
performed (15% [31/213] and 5% [11/213], respectively). The use of erythropoiesis-
stimulating agents was reported by 44% (156/358) of physicians with systematic
iron supplementation for only 47% (74/156) of them. CONCLUSIONS: One of the
main results of this survey is the apparent equation between iron deficiency and
anemia in many physicians. Thus, most physicians report that intravenous iron is
used when hemoglobin is at a median value  8 g/dL, Therefore, iron deficiency is
considered only within a context of severe anemia for many physicians.
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OBJECTIVES: This pilot studywas to evaluate and compare drug eluting stent (DES)
and bare metal stent (BMS) in 1) clinical outcome; 2) humanistic outcome; and 3)
economic outcome, in patients undergoing percutaneous coronary intervention
(PCI). METHODS: All patients undergo PCI in Prince of Wales Hospital during Au-
gust 1 to October 31, 2009 were recruited. Clinical outcome was measured by the
occurrence of major adverse cardiac events (MACE), which is defined as cardiac
death, non-fatal MI and target lesion revascularization. An EQ-5D questionnaire
was used tomeasure the baseline quality of life before the stent placement, and six
months post PCI. Procedural cost including the instruments, medications and hos-
pitalization, as well as all cardiac related follow-up for the first six months was
recorded. Cost to reduce one MACE (ICER) and cost to gain one quality-adjusted
life-year (QALY) was calculated to assess the cost-effectiveness of DES. RESULTS:A
total of 50 patients (n22 and n28 for DES and BMS respectively) were enrolled
into our study. MACE in 6 month was 5% in DES (n1) versus 7% (n2) in BMS
respectively (p0.701). In DES group, the utility score showed significant improve-
ment in six months than baseline (0.92, IQR 0.80–1.00 vs. 0.69, IQR 0.22–0.77,
p0.001), while there were no significant improvement for BMS group (0.87, IQR
0.73–1.00 vs. 0.81, IQR 0.66–1.00, p0.337). ICER calculated was HKD$17,112 and
cost per QALY gained was HKD$142,600. six-month total medical cost was similar,
HKD$92,44058,566 for DES (median$74231) versus $95,22364,301 for BMS (me-
dian$76475) respectively, p0.875, the higher procedural cost of DES group was
balanced by lower follow-up and hospitalization cost, when compared with BMS
group.CONCLUSIONS:Thequality of life of patient underwent placementwithDES
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